Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

metformin plus IUD. Researchers propensity-score ... Results showed no such effect with the addition of GLP-1 receptor agonists to treatment with IUD among women with endometrial polyps or ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...

According to a study published in JAMA Network Open, among patients with type 2 diabetes (T2D), the use of glucagon-like ...

With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. (HealthDay News) — For patients with type 2 diabetes (T2D), glucagon-like ...

The study included patients with T2D prescribed a GLP-1 RA, insulin, or metformin between April 30, 2005, and October 31, 2023 (51,617; 611,115; and 938,602 patients, respectively). Groups were ...